ArticleCureus2024
An Atypical Case of Miller Fisher Syndrome.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Miller Fisher syndrome (MFS) is a rare variant of Guillain-Barré syndrome (GBS) characterized by a classic triad of external ophthalmoplegia, ataxia, and areflexia, often following a recent infection. Understanding atypical presentations of MFS is crucial for timely diagnosis and management, as the syndrome may be mistaken for other neurological disorders. This report aims to highlight the clinical journey of the patient, including symptom onset, diagnostic challenges, and therapeutic interventions, with a discussion of the broader implications of such atypical cases in the context of MFS. In this case, a 28-year-old male presented with binocular diplopia and numbness. The patient had recently returned from Europe, where he experienced a viral diarrheal infection. He presented to the emergency department with diplopia and numbness throughout his entire body and complained of difficulty ambulating because of the loss of sensation in his feet. The examination was significant for binocular diplopia, bilateral disconjugate gaze with esotropia, diminished sensations, and absent deep tendon reflexes in all four extremities, but no ataxia or weakness was elicited. His case was discussed with neurology with concern for GBS or MFS, and he was hesitantly admitted to the floor with a negative inspiratory force (NIF) of -22 (normal < -60) under the resident admitting service. Lumbar puncture (LP) studies including meningitis/encephalitis pathogen panel, venereal disease research laboratory (VDRL), myelin basic protein, anti-GQ1b antibody, and bacterial cultures were initially unremarkable. Even despite suspicion of the diagnosis, no treatment was started until neurology started IV immunoglobulin (IVIG) the next day when his symptoms worsened with bilateral knee weakness. He received five days of 400 mg/kg of IVIG with an improvement of his distal weakness, numbness, and diplopia, as well as respiratory function with a NIF of -48. With an improved ability to ambulate, he was discharged without new medications with a presumed diagnosis of GBS as the gastrointestinal (GI) polymerase chain reaction (PCR) test showed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.